Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. (September 2016)

• Record Type: Journal Article
• Authors: Haumann, J.; Geurts, J.W.; van Kuijk, S.M.J.; Kremer, B.; Joosten, E.A.; van den Beuken-van Everdingen, M.H.J.
• Is Part Of: European journal of cancer. Volume 65(2016)
• Page Start: 121
• Page End: 129
• Publication Date: 2016-09
• Subjects: Methadone -- Fentanyl -- Head-and-neck cancer -- Cancer pain -- NMDA receptor antagonist; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2016.06.025
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: Cancer pain is still inadequately treated in up to 60% of cancer patients. Based on the additional effect on the N-Methyl-d -Aspartate receptor, we expected that methadone (Met) could provide better pain relief than fentanyl (Fen) in cancer pain with a neuropathic pain component. Methods: A randomised controlled trial was performed with 52 strong opioids naive patients with head-and-neck cancer with substantial pain (pain Numerical Rating Scale [NRS] > 4) and a neuropathic pain component (Douleur Neuropathique [DN4] > 4). Twenty-six patients were treated with Met and 26 with Fen. Patients were evaluated at 1, 3 and 5 weeks. The primary outcomes were reduction in average pain, clinical success (defined as 50% average pain decrease) and reduction in pain interference. Secondary outcomes were global perceived effect (GPE) and side-effects. Findings: Reduction in NRS was higher with the use of Met at 1, 3 and 5 weeks (pain change 2.9, 3.1 and 3.1) compared to Fen (1.4, 1.7 and 2.0). This difference was significant at 1 (p = 0.011) and at 3 weeks (p = 0.03). Clinical success (>50% improvement) was higher with Met at 1 week (15% versus 50%, p = 0.012). The change in pain interference, the GPE and side-effect profile were not significantly different between the groups. Interpretation: This is the first study to compare the effects of Met to Fen in cancer patients with a neuropathic pain component. Based on the results of this study, Met should be considered in the treatment of oncological pain with a neuropathic component. Highlights: Methadone results in a better and faster pain relief in the treatment of oncological pain with a neuropathic component as compared with fentanyl. The mean decrease in pain interference is more prominent in methadone treated patients than in fentanyl treated patients. At 1 week significant more patients in the methadone group had a 50% pain relief. There was no significant difference between the groups in percentage of patients with severe side effects.